These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 39066247)

  • 1. Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update.
    Royston L; Papanicolaou GA; Neofytos D
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Razonable RR
    Drug Des Devel Ther; 2024; 18():3987-4001. PubMed ID: 39258274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?
    Monday LM; Keri V; Chandrasekar PH
    Expert Opin Pharmacother; 2024 Apr; 25(6):685-694. PubMed ID: 38717943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients.
    Phoompoung P; Ferreira VH; Tikkanen J; Husain S; Viswabandya A; Kumar D; Humar A
    Transplantation; 2020 Feb; 104(2):404-409. PubMed ID: 32000236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
    Valencia Deray KG; Danziger-Isakov LA; Downes KJ
    J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Real-World Experience With Maribavir for Treatment of Refractory/Resistant Cytomegalovirus in Renal Transplant Recipients.
    Beechar VB; Phadke VK; Pouch SM; Mehta AK; Karadkhele G; Larsen CP; Woodworth MH
    Clin Transplant; 2024 Oct; 38(10):e15480. PubMed ID: 39427300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management.
    Khawaja F; Batista MV; El Haddad L; Chemaly RF
    Curr Opin Infect Dis; 2019 Dec; 32(6):565-574. PubMed ID: 31567572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients.
    Imlay HN; Kaul DR
    Clin Infect Dis; 2021 Jul; 73(1):156-160. PubMed ID: 33197929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
    Veit T; Munker D; Barton J; Milger K; Kauke T; Meiser B; Michel S; Zoller M; Nitschko H; Keppler OT; Behr J; Kneidinger N
    Am J Transplant; 2021 Oct; 21(10):3449-3455. PubMed ID: 34118118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.
    Avery RK; Marty FM; Strasfeld L; Lee I; Arrieta A; Chou S; Tatarowicz W; Villano S
    Transpl Infect Dis; 2010 Dec; 12(6):489-96. PubMed ID: 20682012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
    Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
    Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in cytomegalovirus infection management in solid organ transplant recipients.
    Grossi PA; Peghin M
    Curr Opin Organ Transplant; 2024 Apr; 29(2):131-137. PubMed ID: 38288947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
    Turner N; Strand A; Grewal DS; Cox G; Arif S; Baker AW; Maziarz EK; Saullo JH; Wolfe CR
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxis.
    Saullo JL; Baker AW; Snyder LD; Reynolds JM; Zaffiri L; Eichenberger EM; Ferrari A; Steinbrink JM; Maziarz EK; Bacchus M; Berry H; Kakoullis SA; Wolfe CR
    J Heart Lung Transplant; 2022 Apr; 41(4):508-515. PubMed ID: 35031206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients.
    Linder KA; Kovacs C; Mullane KM; Wolfe C; Clark NM; La Hoz RM; Smith J; Kotton CN; Limaye AP; Malinis M; Hakki M; Mishkin A; Gonzalez AA; Prono MD; Ostrander D; Avery R; Kaul DR
    Transpl Infect Dis; 2021 Aug; 23(4):e13687. PubMed ID: 34251742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update on the management of cytomegalovirus infection in transplant recipients].
    Neofytos D; Van Delden C; Manuel O
    Rev Med Suisse; 2023 Apr; 19(822):726-730. PubMed ID: 37057854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.
    Jaing TH; Wang YL; Chiu CC
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Treatment Options for Refractory/Resistant CMV Infection.
    Walti CS; Khanna N; Avery RK; Helanterä I
    Transpl Int; 2023; 36():11785. PubMed ID: 37901297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.